All In Biotech

Drug Trial Radar · NCT00001038

A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients

A Randomized, Double-Blind Trial of Valacyclovir Hydrochloride (BW 256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients With Advanced HIV Infection (< 100 CD4+ Lymphocytes)

Last checked: Nov 19, 2026Latest source record: Mar 1, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,200

Actual

Start

Not stated

Primary completion

May 1996

Sponsor

Sponsor type
NIH
Collaborators
Glaxo Wellcome
First posted
Aug 31, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Who can join
All sexes, from 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PRIMARY: To evaluate the efficacy of valacyclovir hydrochloride (BW 256U87) in the prevention of cytomegalovirus (CMV) end-organ disease in HIV/CMV co-infected patients with CD4+ lymphocytes \< 100 cells/mm3. To assess the impact of BW 256U87, high-dose oral acyclovir and low-dose oral acyclovir on survival. SECONDARY: To evaluate the effect of BW 256U87 on quality of life, the safety of the drug administered concurrently with standard antiretroviral agents and other essential therapies for the treatment and prevention of opportunistic diseases, and the efficacy of BW 256U87 in suppressing activation of other herpesviruses. To evaluate serologic and virologic risk factors for the development of CMV disease, including assessment of HIV activation, and the risk of developing drug-resistant CMV, HSV, and VZV. Gastrointestinal absorption of acyclovir is not high enough to prevent CMV disease in patients with advanced HIV disease, although there is evidence that high doses of the drug may extend survival. Valacyclovir, a prodrug that is rapidly converted to acyclovir after oral administration, has a higher absorption rate and may therefore provide inhibitory activity against CMV.

Conditions

  • Cytomegalovirus Infections
  • HIV Infections

Interventions

  • Valacyclovir hydrochlorideDrug

  • AcyclovirDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

35 sites in 10 countries. Site status is shown where the registry gives one.

  • Birmingham Veterans Administration Med Ctr

    Birmingham, Alabama

  • Los Angeles County - USC Med Ctr

    Los Angeles, California

  • CARE Ctr / UCLA Med Ctr

    Los Angeles, California

  • Highland Gen Hosp / San Francisco Gen Hosp

    Oakland, California

  • Univ of California / San Diego Treatment Ctr

    San Diego, California

  • Kaiser Permanente Med Ctr

    San Francisco, California

  • Univ of Colorado Health Sciences Ctr

    Denver, Colorado

  • Yale Univ

    New Haven, Connecticut

  • Northwestern Univ Med School

    Chicago, Illinois

  • Indiana Univ Hosp

    Indianapolis, Indiana

  • Johns Hopkins Hosp

    Baltimore, Maryland

  • Harvard (Massachusetts Gen Hosp)

    Boston, Massachusetts

  • Boston Med Ctr

    Boston, Massachusetts

  • Washington Univ

    St Louis, Missouri

  • Mount Sinai Med Ctr

    New York, New York

  • North Central Bronx Hosp / Bronx Municipal Hosp

    The Bronx, New York

  • Univ of North Carolina School of Medicine

    Chapel Hill, North Carolina

  • Ohio State Univ Hosp Clinic

    Columbus, Ohio

  • Girard Med Ctr

    Philadelphia, Pennsylvania

  • Univ TX Galveston Med Branch

    Galveston, Texas

  • Univ of Washington / Madison Clinic

    Seattle, Washington

  • Saint Vincent's Hosp Med Centre

    Sydney, Australia

  • Southern Alberta HIV Clinic / Foothills Hosp

    Calgary, Alberta, Canada

  • Sunnybrook Health Science Ctr

    Toronto, Ontario, Canada

  • Toronto Hosp

    Toronto, Ontario, Canada

  • Montreal Chest Institute

    Montreal, Quebec, Canada

  • Montreal Gen Hosp

    Montreal, Quebec, Canada

  • Hvidovre Univ Hosp

    Hvidore, Denmark

  • Services des Maladies Infectieuses

    Paris, France

  • Universitatsklinikum Rudolf Virchow

    Berlin, Germany

  • Universita Cattolica del Sacro Cuore

    Rome, Italy

  • South Hosp

    Stockholm, Sweden

  • Medizinische Universibatspoliklinik Infekbiologie

    Bern, Switzerland

  • Royal Free Hosp

    London, United Kingdom

  • Westminster Hosp

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.